Influence of smoking history on the evolution of hospitalized in COVID-19 positive patients: results from the SEMI-COVID-19 registry.
Influencia de la historia de tabaquismo en la evolución de la hospitalización en pacientes COVID-19 positivos: datos del registro SEMI-COVID-19.
COVID-19
Hospitalizado
Hospitalized
Mortalidad
Mortality
SARS-CoV-2
Smoking
Tabaquismo
Journal
Medicina clinica
ISSN: 1578-8989
Titre abrégé: Med Clin (Barc)
Pays: Spain
ID NLM: 0376377
Informations de publication
Date de publication:
09 09 2022
09 09 2022
Historique:
received:
24
06
2021
revised:
05
10
2021
accepted:
14
10
2021
pubmed:
14
12
2021
medline:
9
9
2022
entrez:
13
12
2021
Statut:
ppublish
Résumé
Smoking can play a key role in SARS-CoV-2 infection and in the course of the disease. Previous studies have conflicting or inconclusive results on the prevalence of smoking and the severity of the coronavirus disease (COVID-19). Observational, multicenter, retrospective cohort study of 14,260 patients admitted for COVID-19 in Spanish hospitals between February and September 2020. Their clinical characteristics were recorded and the patients were classified into a smoking group (active or former smokers) or a non-smoking group (never smokers). The patients were followed up to one month after discharge. Differences between groups were analyzed. A multivariate logistic regression and Kapplan Meier curves analyzed the relationship between smoking and in-hospital mortality. The median age was 68.6 (55.8-79.1) years, with 57.7% of males. Smoking patients were older (69.9 [59.6-78.0 years]), more frequently male (80.3%) and with higher Charlson index (4 [2-6]) than non-smoking patients. Smoking patients presented a worse evolution, with a higher rate of admission to the intensive care unit (ICU) (10.4 vs 8.1%), higher in-hospital mortality (22.5 vs. 16.4%) and readmission at one month (5.8 vs. 4.0%) than in non-smoking patients. After multivariate analysis, smoking remained associated with these events. Active or past smoking is an independent predictor of poor prognosis in patients with COVID-19. It is associated with higher ICU admissions and in-hospital mortality.
Identifiants
pubmed: 34895891
pii: S0025-7753(21)00650-3
doi: 10.1016/j.medcli.2021.10.011
pmc: PMC8590935
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
spa
Sous-ensembles de citation
IM
Pagination
214-223Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2021 Elsevier España, S.L.U. All rights reserved.
Références
Chest. 2020 Oct;158(4):1770-1776
pubmed: 32561438
Respir Med. 2021 Jan;176:106237
pubmed: 33246296
Int J Environ Res Public Health. 2020 Oct 11;17(20):
pubmed: 33050574
Rev Clin Esp. 2020 Nov;220(8):480-494
pubmed: 33994573
Nicotine Tob Res. 2020 Aug 24;22(9):1650-1652
pubmed: 32242236
Eur J Clin Invest. 2020 Oct;50(10):e13362
pubmed: 32726868
Arch Intern Med. 2004 Nov 8;164(20):2206-16
pubmed: 15534156
Am J Respir Crit Care Med. 2020 Jun 15;201(12):1557-1559
pubmed: 32329629
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Rev Esp Cardiol (Engl Ed). 2022 Feb;75(2):150-158
pubmed: 33685853
Arch Bronconeumol. 2021 Jan;57:21-34
pubmed: 34629638
Nicotine Tob Res. 2020 Aug 24;22(9):1653-1656
pubmed: 32399563
Int J Environ Res Public Health. 2018 May 21;15(5):
pubmed: 29883409
Int J Chron Obstruct Pulmon Dis. 2021 Jan 05;15:3433-3445
pubmed: 33447021
N Engl J Med. 2020 Dec 17;383(25):2451-2460
pubmed: 32412710
MMWR Morb Mortal Wkly Rep. 2020 Apr 03;69(13):382-386
pubmed: 32240123
Respir Med. 2021 Jun;182:106414
pubmed: 33915414
JAMA Intern Med. 2021 May 1;181(5):709-711
pubmed: 33492361
J Med Virol. 2020 Oct;92(10):1915-1921
pubmed: 32293753
Environ Toxicol Pharmacol. 2020 Aug;78:103411
pubmed: 32422280